Dang CT - Search Results

1

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.

Smyth LM, Iyengar NM, Chen MF, Popper SM, Patil S, Wasserheit-Lieblich C, Argolo DF, Singh JC, Chandarlapaty S, Sugarman SM, Comen EA, Drullinsky PR, Traina TA, Troso-Sandoval T, Baselga J, Norton L, Hudis CA, Dang CT. Smyth LM, et al. Among authors: dang ct. Breast Cancer Res Treat. 2016 Jul;158(1):91-97. doi: 10.1007/s10549-016-3851-7. Epub 2016 Jun 15. Breast Cancer Res Treat. 2016. PMID: 27306421 Free PMC article. Clinical Trial.

2

Potential role of selective COX-2 inhibitors in cancer management.

Dang CT, Shapiro CL, Hudis CA. Dang CT, et al. Oncology (Williston Park). 2002 May;16(5 Suppl 4):30-6. Oncology (Williston Park). 2002. PMID: 12102578 Free article. Review.

3

Dose-dense treatment prolongs disease-free survival of women with node positive breast cancer.

Dang C, Seidman AD. Dang C, et al. Cancer Treat Rev. 2003 Oct;29(5):453-6. doi: 10.1016/s0305-7372(03)00164-6. Cancer Treat Rev. 2003. PMID: 12972365 No abstract available.

4

Risk models for neutropenia in patients with breast cancer.

Dang CT, Fornier MN, Hudis CA. Dang CT, et al. Oncology (Williston Park). 2003 Nov;17(11 Suppl 11):14-20. Oncology (Williston Park). 2003. PMID: 14682114 Free article. Review.

5

Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.

Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis CA. Dang CT, et al. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4062-7. doi: 10.1158/1078-0432.CCR-03-0463. Clin Cancer Res. 2004. PMID: 15217939 Clinical Trial.

6

The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma.

Lai R, Dang CT, Malkin MG, Abrey LE. Lai R, et al. Among authors: dang ct. Cancer. 2004 Aug 15;101(4):810-6. doi: 10.1002/cncr.20418. Cancer. 2004. PMID: 15305414 Free article.

7

Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.

Dang CT, D'Andrea GM, Moynahan ME, Dickler MN, Seidman AD, Fornier M, Robson ME, Theodoulou M, Lake D, Currie VE, Hurria A, Panageas KS, Norton L, Hudis CA. Dang CT, et al. Clin Cancer Res. 2004 Sep 1;10(17):5754-61. doi: 10.1158/1078-0432.CCR-04-0634. Clin Cancer Res. 2004. PMID: 15355903 Clinical Trial.

8

Adjuvant therapy for breast cancer: practical lessons from the early breast cancer trialists' collaborative group.

Hudis CA, Dang CT. Hudis CA, et al. Among authors: dang ct. Breast Dis. 2004;21:3-13. doi: 10.3233/bd-2004-21102. Breast Dis. 2004. PMID: 15687717 Review. No abstract available.

9

Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions.

Dang CT. Dang CT. Expert Rev Anticancer Ther. 2006 Mar;6(3):427-36. doi: 10.1586/14737140.6.3.427. Expert Rev Anticancer Ther. 2006. PMID: 16503859 Review.

10

Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective.

Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Robson M, Currie VE, Theodoulou M, Norton L, Hudis C. Hurria A, et al. Breast Cancer Res Treat. 2006 Aug;98(3):343-8. doi: 10.1007/s10549-006-9171-6. Epub 2006 Mar 16. Breast Cancer Res Treat. 2006. PMID: 16541322

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

170 results

Search Page

Filters